Trending...
- Super League (N A S D A Q: SLE) Enters Breakout Phase: New Partnerships, Zero Debt & $20 Million Growth Capital Position Company for 2026 Acceleration
- Entering 2026 with Expanding Footprint, Strong Industry Tailwinds, and Anticipated Q3 Results: Off The Hook YS Inc. (N Y S E American: OTH)
- Coalition and CCHR Call on FDA to Review Electroshock Device and Consider a Ban
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports.
TEMECULA, Calif. - JerseyDesk -- Jellyfish Publication-Certified Nutraceuticals, Inc.
Gerald M. Haase, M.D.
Clinical Professor of Surgery, University of Colorado School of Medicine, Aurora, CO.
Neil E. Wolkodoff, PhD
Medical Program Director, Colorado Center for Health and Sports Science, Denver, CO.
May 16, 2025
Certified Nutraceuticals, Inc., a research and product development enterprise in Pauma Valley, California, U.S.A., announces the publication of an exciting new human clinical trial of its proprietary KollaJell™ collagen peptide formulation.
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports. The strength of this prospective, randomized trial is the distinctive utilization of a panel of brain function metrics from two robust, validated instruments, including a computerized neurocognitive test battery and an electroencephalographic (EEG) profile of voltage activation and wave phase pattern. Instead of evaluating only one or two parameters, this investigation assessed seven domains of cognitive function in 23 subjects who consumed KollaJell™ for a period of eight weeks.
More on Jersey Desk
The outcomes were clinically relevant, and all were statistically analyzed and achieved statistical significance. Standard scores matched for age and gender improved in all metrics regardless of the functional status of where the subject started. The parameters included compositive memory, neurocognitive index, visual memory, executive function and verbal memory. Under EEG monitoring conditions, the mean total reaction time and the trail-making composite test times also decreased dramatically. Topographic brain images showed voltage activation in the brain regions associated with sensory input and processing function. There were no adverse effects of consuming the supplement in any subject at any time during the study.
The importance of this pilot trial is the demonstration of a particularly extensive spectrum of beneficial results from the proprietary formulation compared to competing products that, even if helpful, provide only limited effects. In addition, the use of a marine-based natural collagen was superior to the usual animal-based products and the patented extraction process provided a greater platform of collagen types and a uniquely effective amino acid composition. This human clinical trial reinforces the concept that Certified Nutraceuticals KollaJell™ is a safe and beneficial collagen supplement that supports cognitive domains and memory and is applicable to a wide audience of potential consumers, regardless of their initial brain function status.
More on Jersey Desk
The actual medical study is available as a free open-access publication at https://www.auctoresonline.org/article/effects-of-a-jellyfish-collagen-based-amino-acid-supplement-on-cognitive-function-and-memory-a-pilot-investigation
For further information about the product or study, please contact:
Sara Alkayali at (951) 600-3899 or email: salkayali@certifiednutra.com
Gerald M. Haase, M.D.
Clinical Professor of Surgery, University of Colorado School of Medicine, Aurora, CO.
Neil E. Wolkodoff, PhD
Medical Program Director, Colorado Center for Health and Sports Science, Denver, CO.
May 16, 2025
Certified Nutraceuticals, Inc., a research and product development enterprise in Pauma Valley, California, U.S.A., announces the publication of an exciting new human clinical trial of its proprietary KollaJell™ collagen peptide formulation.
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports. The strength of this prospective, randomized trial is the distinctive utilization of a panel of brain function metrics from two robust, validated instruments, including a computerized neurocognitive test battery and an electroencephalographic (EEG) profile of voltage activation and wave phase pattern. Instead of evaluating only one or two parameters, this investigation assessed seven domains of cognitive function in 23 subjects who consumed KollaJell™ for a period of eight weeks.
More on Jersey Desk
- DominoZee Drops a Rebel-Made Apparel Line Redefining Modern Street Culture
- Kentucky Judges Ignore Evidence, Prolong Father's Ordeal in Baseless Case
- Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor
- Rigani Press Announces Barnes & Noble Book Signing for Dr. S. Yin Ho's Groundbreaking Book
- Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform
The outcomes were clinically relevant, and all were statistically analyzed and achieved statistical significance. Standard scores matched for age and gender improved in all metrics regardless of the functional status of where the subject started. The parameters included compositive memory, neurocognitive index, visual memory, executive function and verbal memory. Under EEG monitoring conditions, the mean total reaction time and the trail-making composite test times also decreased dramatically. Topographic brain images showed voltage activation in the brain regions associated with sensory input and processing function. There were no adverse effects of consuming the supplement in any subject at any time during the study.
The importance of this pilot trial is the demonstration of a particularly extensive spectrum of beneficial results from the proprietary formulation compared to competing products that, even if helpful, provide only limited effects. In addition, the use of a marine-based natural collagen was superior to the usual animal-based products and the patented extraction process provided a greater platform of collagen types and a uniquely effective amino acid composition. This human clinical trial reinforces the concept that Certified Nutraceuticals KollaJell™ is a safe and beneficial collagen supplement that supports cognitive domains and memory and is applicable to a wide audience of potential consumers, regardless of their initial brain function status.
More on Jersey Desk
- IODefi Introduces New Web3 Infrastructure Framework as XRP Ledger Development Gains Global Attention
- Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
- EnergyStrat Launches Global LNG Risk Outlook 2025–2030
- Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
- MDC Design Center Expands Kitchen and Bath Remodeling Solutions in Cherry Hill for 2026
The actual medical study is available as a free open-access publication at https://www.auctoresonline.org/article/effects-of-a-jellyfish-collagen-based-amino-acid-supplement-on-cognitive-function-and-memory-a-pilot-investigation
For further information about the product or study, please contact:
Sara Alkayali at (951) 600-3899 or email: salkayali@certifiednutra.com
Source: Certified Nutraceuticals, Inc.
Filed Under: Health
0 Comments
Latest on Jersey Desk
- Give From the Heart: FL Chamber Holiday Toy & Clothing Drive
- Naturism Resurgence (NRE) Announces the World's First Standardised Stigma Measure (SSM) for Naturism
- London Art Exchange Emerges as a Leading Force in UK Contemporary Art, Elevating Three Artists to Secondary-Market Success
- myLAB Box Expands, Becoming the First and Only At-Home Testing Company to Serve the Entire Family—Human and Furry—with New Pet Intolerance Test
- Entering 2026 with Expanding Footprint, Strong Industry Tailwinds, and Anticipated Q3 Results: Off The Hook YS Inc. (N Y S E American: OTH)
- Tiger-Rock Martial Arts Appoints Jami Bond as Vice President of Growth
- CCM Announces Executive Promotions
- Super League (N A S D A Q: SLE) Enters Breakout Phase: New Partnerships, Zero Debt & $20 Million Growth Capital Position Company for 2026 Acceleration
- Finland's Gambling Reform Promises "Single-Click" Block for All Licensed Sites
- Private Keys Are a Single Point of Failure: Security Advisor Gideon Cohen Warns MPC Technology Is Now the Only Defense for Institutional Custody
- Compliance Is the Ticket to Entry: Legal Advisor Gabriela Moraes Analyzes RWA Securitization Paths Under Brazil's New Legislation
- Coalition and CCHR Call on FDA to Review Electroshock Device and Consider a Ban
- Voxmedia LLC awarded ACCME Accreditation with Commendation
- Spark Announces 2025 Design Award Winners
- NEW Luxury Single-Family Homes Coming Soon to Manalapan - Pre-Qualify Today for Priority Appointments
- Dominic Pace Returns to the NCIS Franchise With Guest Role on NCIS: Origins
- Anderson Periodontal Wellness Attends 5th Joint Congress for Ceramic Implantology
- UK Financial Ltd Completes Full Ecosystem Conversion With Three New ERC-3643 SEC-Ready Tokens As MCAT Deadline Closes Tonight
- AI Real Estate Company Quietly Building a National Powerhouse: reAlpha Tech Corp. (N A S D A Q: AIRE)
- Inkdnylon Expands National Uniform Embroidery Services


